Cargando…

Diabetes Insipidus Induced by Combination of Short-acting Octreotide and Lanreotide for Recurrent Carcinoid Crisis of Neuroendocrine Tumour: A Case Report

Somatostatin analogue is useful in carcinoid crisis for symptom control. Optimal dosing of somatostatin analogues for carcinoid symptoms is not known. This case highlighted management issues using combination short-acting octreotide infusion with long-acting lanreotide during carcinoid crisis. The p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guan, Goh Kian, Rajoo, Subashini, Dusa, Noraini Mohd, Yahya, Nik Hasimah Nik, Bidin, Mohamed Badrulnizam Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Journal of the ASEAN Federation of Endocrine Societies 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666490/ https://www.ncbi.nlm.nih.gov/pubmed/34966210 http://dx.doi.org/10.15605/jafes.036.02.09

Ejemplares similares

Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors
por: Wolin, Edward M., et al.
Publicado: (2016)

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
por: Saif, Muhammad Wasif, et al.
Publicado: (2018)

Rare Case of Large Catecholamine Secreting Ganglioneuroma in an Asymptomatic Elderly Male
por: Soundarajan, Tivya, et al.
Publicado: (2022)

Cryptorchidism is a Useful Clue for Idiopathic Hypogonadotropic Hypogonadism in Pituitary Stalk Thickening
por: Nagaratnam, Shamharini, et al.
Publicado: (2021)

Unusual presentation of lung carcinoma with pituitary metastasis: a challenging diagnosis and sodium management dilemmas
por: Wong, Poh Shean, et al.
Publicado: (2022)

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis
por: Ryan, P, et al.
Publicado: (2019)

A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide
por: Yamaoka, Keiko, et al.
Publicado: (2021)

MON-911 Debilitating Neuropsychiatry Symptoms in Pancreatic Insulinoma Co-Secreting Serotonin and IGF-1
por: Azman, Siti Sanaa Wan, et al.
Publicado: (2020)

Citalopram/octreotide: Carcinoid heart disease, unmasking of carcinoid syndrome and development of octreotide resistance: case report
Publicado: (2021)

Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
por: Tutuncu, Yasemin, et al.
Publicado: (2011)

Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling
por: Ungefroren, Hendrik, et al.
Publicado: (2022)

Real world use of lanreotide in neuroendocrine tumors
por: Siddiqui, Zeba, et al.
Publicado: (2023)

Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)
por: Adelman, Daphne, et al.
Publicado: (2020)

A Cross-sectional Study to Assess Beta-Cell Function in Individuals with Recently Diagnosed Young-Onset Type 2 Diabetes Mellitus and Its’ Complications
por: Nagaratnam, Shamharini, et al.
Publicado: (2023)

Clinical utility of lanreotide Autogel(®) in gastroenteropancreatic neuroendocrine tumors
por: Paragliola, Rosa Maria, et al.
Publicado: (2016)

Everolimus in combination with octreotide LAR in thymic atypical carcinoid
por: Sakane, Tadashi, et al.
Publicado: (2023)

Metastatic Recurrence of Typical Pulmonary Carcinoid Accompanied by Carcinoid Syndrome, Successfully Treated with Octreotide LAR
por: Yanagisawa, Asako, et al.
Publicado: (2017)

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
por: Yau, Hanford, et al.
Publicado: (2017)

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
por: Neggers, Sebastian JCMM, et al.
Publicado: (2015)

A Challenging Case of Carcinoid Crisis in a Patient With Neuroendocrine Tumor
por: Mahdi, Mohammed, et al.
Publicado: (2021)

MON-LB47 An International Simulated Use Study (PRESTO) to Evaluate Nurse Preferences Between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe
por: Adelman, Daphne T, et al.
Publicado: (2020)

Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms
por: Laskaratos, Faidon-Marios, et al.
Publicado: (2019)

Metastatic thymic carcinoid responds to chemoradiation and octreotide: A case report
por: Mei, Zhu, et al.
Publicado: (2018)

Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
por: Nilsson, O., et al.
Publicado: (1998)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors
por: Cheng, Yue, et al.
Publicado: (2023)

Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide
por: Kos-Kudła, Beata, et al.
Publicado: (2017)

Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
por: Sciammarella, Concetta, et al.
Publicado: (2020)

First Case of Regression of Carcinoid Heart Disease on Serial Transthoracic Echocardiograms following Octreotide Monotherapy in a Patient with Metastatic Pancreatic Neuroendocrine Tumor
por: Nath, Ermin, et al.
Publicado: (2020)

A case of metastatic neuroendocrine disease and cholecystitis: surgical remedy and management of carcinoid crisis
por: Whiley, Phillip J, et al.
Publicado: (2021)

A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial
por: Blot, Koenraad, et al.
Publicado: (2019)

Metastatic hepatic carcinoid associated with ectopic ACTH syndrome, resistant to octreotide and ketoconazole therapy
por: Khan, Mohammed Qassim, et al.
Publicado: (2004)

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis
por: Strosberg, Jonathan R, et al.
Publicado: (2015)

High-Dose Lanreotide in the Treatment of Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: A Case Report
por: Van Fraeyenhove, Frank, et al.
Publicado: (2014)

Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism
por: Corda, Heike, et al.
Publicado: (2017)

Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study
por: von Arx, Claudia, et al.
Publicado: (2020)

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
por: Caplin, Martyn E, et al.
Publicado: (2016)

Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel(®): A Case Report
por: Lybaert, Willem, et al.
Publicado: (2014)

Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors
por: Ito, Tetsuhide, et al.
Publicado: (2017)

Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results
por: Raderer, M, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_ft9jfnh5h8kmkl1trgi91edjh6